Atypical intraductal proliferation (AIP) of the prostate: a borderline lesion with important clinical implications
Precision Pathology · 2026
DOI: 10.1016/j.prpath.2026.100004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Precision Pathology, 2026. Verfasst von Enrico Munari und 15 weiteren Autor:innen. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Atypical intraductal proliferation (AIP) of the prostate is a borderline intraductal lesion characterized by architectural complexity and/or cytological atypia exceeding that of high-grade prostatic intraepithelial neoplasia (HGPIN), but insufficient for a definitive diagnosis of intraductal carcinoma of the prostate (IDC-P). Its recognition has gained increasing importance because emerging evidence, derived largely from studies in which AIP was diagnosed by genitourinary pathologists applying a relatively high morphologic threshold, indicates that AIP is frequently associated with unsampled adverse pathology, including IDC-P, large cribriform carcinoma, higher Grade Group disease and extraprostatic extension. Morphologically, AIP most commonly shows loose cribriform or complex micropapillary intraductal growth with retained basal cells, lacking the dense cribriform or solid architecture, marked pleomorphism or comedonecrosis required for IDC-P. Immunophenotypic and molecular studies further support its biological relationship with IDC-P and adjacent invasive carcinoma, particularly through concordant ERG overexpression and PTEN loss, while recent biomarker data suggest that AIP may share features with more advanced intraductal proliferations rather than conventional HGPIN. Nevertheless, AIP remains a diagnostic grey zone, and its clinical meaning depends on the diagnostic threshold applied. Formal interobserver reproducibility data for AIP are still lacking, and reproducibility remains one of the major unresolved challenges in this area. Recent debate and joint GUPS–ISUP recommendations support restricting the term to lesions genuinely suspicious for IDC-P but falling short of definitive criteria, preferably reported as “AIP, suspicious for IDC-P.” AIP should not be incorporated into the Gleason score. Because no management algorithm has been prospectively validated for AIP, careful clinicopathologic correlation, consideration of ancillary studies in selected cases, MRI correlation and additional or targeted sampling are reasonable considerations rather than evidence-based mandates. AIP does not in itself preclude active surveillance, but its presence should prompt reassessment of sampling adequacy and of the individual risk of unsampled adverse pathology.
Zitieren
APA
Munari, E., Polati, R., Antonini, P., Segala, D., Cima, L., Porcaro, A. B., Antonelli, A., Bertolo, R. G., Bogina, G., Tavora, F., Acosta, A. M., Caliò, A., Faryna, K., Litjens, G., Martignoni, G., & Brunelli, M. (2026). Atypical intraductal proliferation (AIP) of the prostate: a borderline lesion with important clinical implications. Precision Pathology. https://doi.org/10.1016/j.prpath.2026.100004
Vancouver
Munari E, Polati R, Antonini P, Segala D, Cima L, Porcaro AB, et al. Atypical intraductal proliferation (AIP) of the prostate: a borderline lesion with important clinical implications. Precision Pathology. 2026. doi:10.1016/j.prpath.2026.100004
BibTeX
@article{Munari2026,
author = {Munari, Enrico and Polati, Rita and Antonini, Pietro and Segala, Diego and Cima, Luca and Porcaro, Antonio Benito and Antonelli, Alessandro and Bertolo, Riccardo G. and Bogina, Giuseppe and Tavora, Fabio and Acosta, Andres M. and Caliò, Anna and Faryna, Khrystyna and Litjens, Geert and Martignoni, Guido and Brunelli, Matteo},
title = {Atypical intraductal proliferation (AIP) of the prostate: a borderline lesion with important clinical implications},
journal = {Precision Pathology},
year = {2026},
doi = {10.1016/j.prpath.2026.100004}
}
EUVIMED